Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Circulating Tumor DNA Based Minimal Residual Disease Detection in Early Stage Breast Cancer Patients: A Prospective Study

NCT07136493 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07136493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Circulating Tumor DNA Based Minimal Residual Disease Detection in Early Stage Breast Cancer Patients: A Prospective Study
Lead sponsor
City of Hope Medical Center
Phase
Not applicable
Overall status
Withdrawn
Start date
May 12, 2026
Completion date
June 16, 2026
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, estrogen receptor-positive breast carcinoma, her2-negative breast carcinoma, her2-positive breast carcinoma, triple-negative breast carcinoma